The Patent Finder

Addex Pharma, S.A.

8 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Nov 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 7, 2027
    The maintenance fee for Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors (US 9,073,907) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
  • 1 fee due Feb 25, 2027
    The maintenance fee for 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4'] BIPYRIDINYL-2'-ONES (US 9,114,138) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
  • 1 fee due Mar 15, 2027
    The maintenance fee for 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']BIPYRIDINYL-2'-ONES (US 9,132,122) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,132,1221',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']BIPYRIDINYL-2'-ONES
In force
 · High confidence
In forceHigh confidence
US 8,344,138Novel Triazinedione Derivatives as Gabab Receptor Modulators
In force
 · High confidence
In forceHigh confidence
US 9,114,1381',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4'] BIPYRIDINYL-2'-ONES
In force
 · High confidence
In forceHigh confidence
US 9,737,5331,2,4-Triazolo [4,3-a] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders
In force
 · Medium confidence
In forceMedium confidence
US 8,716,4807-Aryl-1,2,4-triazolo[4,3-a]pyridine Derivatives and Their Use as Positive Allosteric Modulators of MGLUR2 Receptors
In force
 · High confidence
In forceHigh confidence
US 8,937,0601,2,4-Triazolo [4,3-a] Pyridine Derivatives and Their Use for the Treatment of Prevention of Neurological and Psychiatric Disorders
In force
 · High confidence
In forceHigh confidence
US 9,073,907Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
In force
 · USPTO record
In forceUSPTO record
US 9,938,270Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 8: 1 patent in force now held by others · 29 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 abandoned · 14 no status recorded

Showing 1 to 10 of 17, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/560,011Substituted Heterobicyclic Derivatives as Negative Allosteric Modulators of MGLU7 ReceptorMay 13, 2022Pending
18/559,951Fused Heterocyclic Derivatives as Negative Allosteric Modulators of MGLU7 ReceptorMay 13, 2022Pending
17/354,194Jun 22, 2021No status recorded
14/817,676Aug 4, 2015No status recorded
14/306,215Novel Triazinedione Derivatives as Gabab Receptor ModulatorsJun 16, 2014Abandoned
13/747,411Jan 22, 2013No status recorded
14/372,986Jan 18, 2013No status recorded
13/695,918May 5, 2011No status recorded
13/695,654May 5, 2011No status recorded
13/640,332Apr 20, 2011No status recorded
10 of 17 applications shown.
Pro members see all 17 published applications.
Pro members: see all 17 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited